Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
Official title:
Tailored Implementation for Chronic Diseases.
Background: Chronic Obstructive Pulmonary Disease (COPD) remains a major health problem,
which is strongly related to smoking. Despite publication of guidelines on the prevention
and treatment of COPD, not all COPD patients receive the best available healthcare.
Investigators developed a tailored implementation strategy for improving primary care
physicians' adherence to COPD management guidelines. The primary aim of the presented trial
is to evaluate the effects of this strategy on physician's performance. The secondary aim is
to examine the validity of the tailoring of implementation interventions.
Primary Trial Hypothesis: To study if the rate of adherence to the COPD guideline over a 1
year will increase among participants assigned to the intervention group in comparison to
those assigned to the control group?
Methods/Design: A two-arm pragmatic cluster randomized trial is planned. A total of 540
patients with diagnosed COPD will be included from 18 general practices in Poland. A
tailored implementation program will be offered to general practitioners. Participating
physicians in the intervention practices (n=18) will receive training to provide brief
anti-smoking counselling. An additional form containing COPD severity scale will be inserted
into patient's medical records. The checklist with key information about the disease and its
management while consulting a patient with COPD will be provided to practitioners.
Investigators will provide practices with training inhaler devices for general practitioners
(GPs) to teach patients in correct use of each device and to note this education/training in
patient's medical records. The control practices will provide usual care.
Discussion: The results of this trial will be directly applicable to primary care in Poland
and add to the growing body of evidence on interventions to improve chronic illness care.
Chronic Obstructive Pulmonary Disease (COPD) remains a major health problem. Worldwide it
has been ranked as the sixth leading cause of death for both genders. In 2020 COPD is
projected to rank fifth worldwide in burden of disease. It is also projected to be the
fourth leading cause of death worldwide by 2030 due to an increase in smoking rates and
demographic changes in many countries. The national survey conducted in Poland in 2007
indicated that 34% of men smoked daily, 2% were occasional smokers, 19% were former smokers
and 45% never smoked. In women, these percentages were, respectively, 23%, 3%, 10% and 64%.
Although COPD has received increasing attention from the medical community in some countries
in recent years, it is still relatively unknown or ignored by the public as well as many
healthcare providers and government officials.
Epidemiological studies of COPD on a representative sample have not been performed in
Poland, but estimates from smaller suggested a relatively high prevalence. Studies which
covered a selected geographical population found that signs and symptoms of COPD are seen in
about 10% of patients over 40 years old. Studies in big cities in Poland showed a 9,8%
prevalence of COPD in populations between 41 and 72 years old. These data are similar to
European data, describing prevalence rates of 4-11% of COPD in adults in Europe. The
absolute number of people suffering from COPD in Poland is estimated on about 2 million.
This places COPD as the third most frequent - concerning frequency - chronic illness, and it
is the fourth most common cause of death in Poland.
In Poland, many guidelines on COPD are used, some of which are national and some are
international. There is no guideline in Poland which is designed for primary care.
Implementation of interventions directed on health professionals knowledge programme can
change the professionals behavior. In this study the support strategy is applied to improve
implementation process.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 | |
Terminated |
NCT01388920 -
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
|
Phase 2 |